Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bavarian Nordic A/S's CV-301 Cancer Immunotherapy Candidate Shows Promise In Colorectal Cancer


Wednesday, 29 May 2013 01:44am EDT 

Bavarian Nordic A/S announced that promising data from a Phase 2 trial of its CV-301 cancer immunotherapy candidate in patients with resected metastatic colorectal cancer were recently published in the Annals of Surgery. In a study conducted at Duke University, 74 patients who were disease free after surgical resection of metastatic colon cancer received chemotherapy followed by immunotherapy with CV-301 (formerly designated as PANVAC-VF) either as CV-301 modified dendritic cells or in combination with GM-CSF. Compared to a group of contemporary control patients who were matched for key clinical features and had similar surgery and chemotherapy, the overall survival of the CV-301 treated patients was significantly longer (p < 0.0001). Treatment with CV-301 was well tolerated, with injection site reactions, fever, fatigue and muscle soreness as the most common side effects. Bavarian Nordic has expanded its license with the National Cancer Institute (NCI) for CV-301 to include colon cancer. The original collaboration agreement was executed in 2011, and involved multiple cancers including breast, lung, ovarian and other cancers. Colorectal cancer is the most frequently diagnosed cancer and second leading cause of cancer death in developed countries, according to the American Cancer Society. 

Company Quote

296.0
-10.5 -3.43%
6 May 2015